<DOC>
	<DOC>NCT00986531</DOC>
	<brief_summary>The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.</brief_summary>
	<brief_title>The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>DSMIV diagnosis of schizophrenia or schizoaffective disorder ECT in the last 6 months Substance abuse or dependence History of claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>early phase trials</keyword>
</DOC>